Viking Therapeutics (VKTX) Leerink Global Healthcare Conference 2026 summary

Key clinical progress and data readouts

• Two phase III trials for the dual agonist VK2735 (VANQUISH-1 and VANQUISH-2) were initiated in 2025, with enrollment progressing faster than expected.

• Oral formulation phase II data showed a strong profile, leading to phase III initiation in Q3 2026; four phase III trials will be ongoing by year-end.

• Maintenance study will provide key data in Q3 2026, evaluating transitions from weekly to monthly or oral dosing.

• Phase II results showed about 15% weight loss in 13 weeks at 15 mg, with expectations to be competitive or superior to GLP-1 monoagonists.

• Safety and GI tolerability were favorable, with side effects mostly in the first 4-6 weeks and mitigated by lower starting doses and gradual titration.

Differentiation and product profile

• VK2735 has a longer half-life (8-9 days) and higher Cmax than competitors, potentially enabling less frequent dosing and improved efficacy.

• Maintenance study explores weekly, biweekly, monthly, and oral regimens, aiming to optimize convenience and efficacy.

• Having both subQ and oral options with the same molecule allows for seamless patient transitions and potentially improved tolerability.

• Oral phase III trials will be smaller and more cost-efficient by leveraging subQ safety data, reducing trial size by about 75%.

Commercial strategy and market outlook

• Commercial plans focus on capturing 5-10% market share, leveraging nimbleness and targeting specific segments, including ex-US and cash pay markets.

• Pricing is expected to remain stable due to a rational duopoly, with less impact from list price reductions and more focus on net pricing.

• Commercialization will utilize capital-light, efficient models and channel partners for direct-to-consumer marketing.

• Market segmentation is expected to increase, with different patient preferences for dosing frequency and formulation.